Continuous overall equipment effectiveness can be used to pinpoint hidden downtime and process bottlenecks in real time.
|Articles|May 2, 2011
- Pharmaceutical Technology-05-02-2011
- Volume 35
- Issue 5
Pharmaceutical Technology, May 2011 Issue (PDF)
Up Close and Personal
Advertisement
Articles in this issue
over 15 years ago
Report from Hungaryover 15 years ago
INTERPHEX Innovationsover 15 years ago
Supply Chain Painover 15 years ago
In the Spotlight May 2011over 15 years ago
Up Close and Personalover 15 years ago
Gelatin Capsule Shell Cross-Linkingover 15 years ago
Q&A with Greg Irace,sanofi-aventisover 15 years ago
Pharmaceutical Excipients for Hot-Melt Extrusionover 15 years ago
Global Healthcare on the Ground: Roche Takes on Illnesses in LDCsover 15 years ago
Beyond MicronizationAdvertisement
Related to this article
Subathra Ramamoorthy, Veranova, on how forced degradation and trace impurity profiling in potent APIs shape regulator-ready analytical methods.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
2
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
AAPS PharmSci 360 2026: Spray Drying and ASD
5